Carmustine

Lymphoma, Non-Hodgkin, Glioblastoma, Refractory Multiple Myeloma + 9 more
Treatment
20 Active Studies for Carmustine

What is Carmustine

CarmustineThe Generic name of this drug
Treatment SummaryAlkylating antineoplastic is a type of medication used to treat cancer by targeting cells in any stage of the cell cycle. It is most often used to treat brain tumors and other types of cancer. The use of this drug may increase the risk of developing cancer.
Gliadelis the brand name
image of different drug pills on a surface
Carmustine Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Gliadel
Carmustine
1996
17

Effectiveness

How Carmustine Affects PatientsCarmustine is a medication used to treat brain tumors, multiple myeloma, Hodgkin's disease, and non-Hodgkin's lymphomas. It works by affecting both DNA and RNA structures, and is not related to any other alkylators. It may also affect key enzymes by attaching to proteins in the body.
How Carmustine works in the bodyCarmustine works by blocking DNA and RNA production which prevents the body from making proteins. It also binds to and changes an enzyme which leads to cell death.

When to interrupt dosage

The recommended dosage of Carmustine is contingent upon the identified condition, like Glioblastoma, Recently Identified High Grade Glioma (HGG) and Medulloblastomas. Dosage is subject to the technique of delivery, as presented in the following table.
Condition
Dosage
Administration
Mycosis Fungoides (MF)
, 7.7 mg, 100.0 mg, 10.0 mg/mL
, Intracavitary, Wafer, Wafer - Intracavitary, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Intralesional, Wafer - Intralesional, Kit, Injection, powder, for solution, Kit - Intravenous, Injection, powder, for solution - Intravenous
Hodgkin Disease
, 7.7 mg, 100.0 mg, 10.0 mg/mL
, Intracavitary, Wafer, Wafer - Intracavitary, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Intralesional, Wafer - Intralesional, Kit, Injection, powder, for solution, Kit - Intravenous, Injection, powder, for solution - Intravenous
Astrocytomas
, 7.7 mg, 100.0 mg, 10.0 mg/mL
, Intracavitary, Wafer, Wafer - Intracavitary, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Intralesional, Wafer - Intralesional, Kit, Injection, powder, for solution, Kit - Intravenous, Injection, powder, for solution - Intravenous
Brain Stem Gliomas
, 7.7 mg, 100.0 mg, 10.0 mg/mL
, Intracavitary, Wafer, Wafer - Intracavitary, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Intralesional, Wafer - Intralesional, Kit, Injection, powder, for solution, Kit - Intravenous, Injection, powder, for solution - Intravenous
Metastatic Brain Tumors
, 7.7 mg, 100.0 mg, 10.0 mg/mL
, Intracavitary, Wafer, Wafer - Intracavitary, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Intralesional, Wafer - Intralesional, Kit, Injection, powder, for solution, Kit - Intravenous, Injection, powder, for solution - Intravenous
Medulloblastomas
, 7.7 mg, 100.0 mg, 10.0 mg/mL
, Intracavitary, Wafer, Wafer - Intracavitary, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Intralesional, Wafer - Intralesional, Kit, Injection, powder, for solution, Kit - Intravenous, Injection, powder, for solution - Intravenous
Refractory Multiple Myeloma
, 7.7 mg, 100.0 mg, 10.0 mg/mL
, Intracavitary, Wafer, Wafer - Intracavitary, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Intralesional, Wafer - Intralesional, Kit, Injection, powder, for solution, Kit - Intravenous, Injection, powder, for solution - Intravenous
Newly Diagnosed High Grade Glioma (HGG)
, 7.7 mg, 100.0 mg, 10.0 mg/mL
, Intracavitary, Wafer, Wafer - Intracavitary, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Intralesional, Wafer - Intralesional, Kit, Injection, powder, for solution, Kit - Intravenous, Injection, powder, for solution - Intravenous
Glioblastoma
, 7.7 mg, 100.0 mg, 10.0 mg/mL
, Intracavitary, Wafer, Wafer - Intracavitary, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Intralesional, Wafer - Intralesional, Kit, Injection, powder, for solution, Kit - Intravenous, Injection, powder, for solution - Intravenous
Glioblastoma
, 7.7 mg, 100.0 mg, 10.0 mg/mL
, Intracavitary, Wafer, Wafer - Intracavitary, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Intralesional, Wafer - Intralesional, Kit, Injection, powder, for solution, Kit - Intravenous, Injection, powder, for solution - Intravenous
Lymphoma, Non-Hodgkin
, 7.7 mg, 100.0 mg, 10.0 mg/mL
, Intracavitary, Wafer, Wafer - Intracavitary, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Intralesional, Wafer - Intralesional, Kit, Injection, powder, for solution, Kit - Intravenous, Injection, powder, for solution - Intravenous
Ependymomas
, 7.7 mg, 100.0 mg, 10.0 mg/mL
, Intracavitary, Wafer, Wafer - Intracavitary, Powder, for solution, Intravenous, Powder, for solution - Intravenous, Intralesional, Wafer - Intralesional, Kit, Injection, powder, for solution, Kit - Intravenous, Injection, powder, for solution - Intravenous

Warnings

Carmustine Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Carmustine may interact with Pulse Frequency
There are 20 known major drug interactions with Carmustine.
Common Carmustine Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Carmustine is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Carmustine is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abetimus
Major
The risk or severity of adverse effects can be increased when Carmustine is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Carmustine is combined with Acteoside.
Aldosterone
Major
The risk or severity of adverse effects can be increased when Carmustine is combined with Aldosterone.
Carmustine Toxicity & Overdose RiskThe lowest toxic dose of the drug in rats and mice is 20mg/kg and 45mg/kg respectively. Common side effects are low white blood cell count, low platelet count, and nausea. Severe toxic effects can include scarring of the lungs (20-0%) and damage to the bone marrow.
image of a doctor in a lab doing drug, clinical research

Carmustine Novel Uses: Which Conditions Have a Clinical Trial Featuring Carmustine?

166 active trials are currently testing the potential of Carmustine in managing Newly Diagnosed High Grade Glioma (HGG), Hodgkin Disease and Non-Hodgkin Lymphoma.
Condition
Clinical Trials
Trial Phases
Glioblastoma
77 Actively Recruiting
Phase 3, Phase 1, Phase 2, Early Phase 1, Not Applicable
Refractory Multiple Myeloma
47 Actively Recruiting
Phase 3, Phase 1, Phase 2, Not Applicable
Metastatic Brain Tumors
59 Actively Recruiting
Phase 1, Phase 2, Not Applicable, Early Phase 1, Phase 3, Phase 4
Newly Diagnosed High Grade Glioma (HGG)
0 Actively Recruiting
Mycosis Fungoides (MF)
0 Actively Recruiting
Brain Stem Gliomas
3 Actively Recruiting
Phase 2, Phase 1
Ependymomas
0 Actively Recruiting
Lymphoma, Non-Hodgkin
0 Actively Recruiting
Astrocytomas
0 Actively Recruiting
Glioblastoma
2 Actively Recruiting
Phase 1
Medulloblastomas
0 Actively Recruiting
Hodgkin Disease
18 Actively Recruiting
Phase 1, Phase 2, Early Phase 1

Carmustine Reviews: What are patients saying about Carmustine?

3Patient Review
4/14/2016
Carmustine for Malignant Brain Tumor Glioblastoma
I received this treatment every two weeks and saw my blood counts and platelets drop. Despite this, the tumor continued to grow.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about carmustine

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is a long term side effect of carmustine?

"Carmustine may cause serious pneumonitis and pulmonary fibrosis (a scarring and stiffening of the lung tissue)

Carmustine may cause serious inflammation of the lungs and scarring of the lung tissue, which can make the lungs stiff and difficult to breathe. These problems can develop months to years after treatment is completed and may be more common in people with pre-existing lung conditions."

Answered by AI

What type of drug is carmustine?

"Carmustine is a medication that belongs to a group of drugs called alkylating agents. These drugs work by preventing the cancer cells from growing and multiplying."

Answered by AI

What is carmustine used to treat?

"Carmustine is a chemotherapy drug, also known by its brand name BCNU. It is a treatment for brain tumours, non Hodgkin's lymphoma and Hodgkin's lymphoma. For adults with a type of brain tumour called glioma, doctors might use a form of carmustine called Gliadel wafers."

Answered by AI

Clinical Trials for Carmustine

Have you considered Carmustine clinical trials? We made a collection of clinical trials featuring Carmustine, we think they might fit your search criteria.
Have you considered Carmustine clinical trials? We made a collection of clinical trials featuring Carmustine, we think they might fit your search criteria.
Have you considered Carmustine clinical trials? We made a collection of clinical trials featuring Carmustine, we think they might fit your search criteria.